ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Eisai Co., Ltd.

Business Summary

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue645,942M6,090.49M
Gross Profit465,186M4,386.17M
Operating income56,543M533.13M
Income before tax52,551M495.49M
Net income42,119M397.13M
EBITDA92,842M875.39M
Diluted EPS146.901.38
Dividends Per Share1601.50
Total Assets1,090.00B9,864.33M
Total liabilities362,067M3,276.62M
Total equity703,183M6,363.64M
Operating cash flow73,853M696.34M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 539,097M 600,054M 642,834M 695,621M 645,942M
Gross Profit 331,091M 386,599M 446,436M 510,352M 465,186M
Operating income 51,205M 75,595M 99,921M 138,679M 56,543M
Income before tax 57,668M 76,803M 89,454M 128,063M 52,551M
Net income 39,359M 51,845M 63,386M 121,767M 42,119M
EBITDA 77,689M 101,778M 126,762M 172,379M 92,842M
Diluted EPS 137.41 180.97 221.11 424.79 146.90
Dividends Per Share 150 150 150 160 160
Total Assets 1,030.76B 1,049.03B 1,071.52B 1,062.14B 1,090.00B
Total liabilities 428,172M 434,934M 419,539M 359,509M 362,067M
Total equity 584,630M 593,582M 628,120M 678,127M 703,183M
Operating cash flow 75,851M 149,649M 103,714M 102,782M 73,853M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 4,978.38M 5,414.06M 5,796.79M 6,397.94M 6,090.49M
Gross Profit 3,057.51M 3,488.14M 4,025.76M 4,693.93M 4,386.17M
Operating income 472.86M 682.06M 901.04M 1,275.49M 533.13M
Income before tax 532.54M 692.96M 806.65M 1,177.85M 495.49M
Net income 363.46M 467.77M 571.58M 1,119.94M 397.13M
EBITDA 717.43M 918.30M 1,143.08M 1,585.44M 875.39M
Diluted EPS 1.26 1.63 1.99 3.90 1.38
Dividends Per Share 1.38 1.35 1.35 1.47 1.50
Total Assets 9,250.32M 9,863.94M 9,680.80M 9,838.72M 9,864.33M
Total liabilities 3,842.51M 4,089.64M 3,790.38M 3,330.17M 3,276.62M
Total equity 5,246.61M 5,581.39M 5,674.84M 6,281.57M 6,363.64M
Operating cash flow 700.45M 1,350.22M 935.24M 945.33M 696.34M

Valuation Measures

Mar 2021
PER50.48
ROA3.91%
ROE6.09%
Operating margin8.75%
Profit margin6.52%

Key executives

  • Chief Executive Officer & Representative Director: Haruo Naito
  • COO, Representative Executive Officer & Head-China: Yasushi Okada
  • Chief Financial Officer: Ryohei Yanagi
  • Chief Medical Officer & Managing Executive Officer: Edward Stewart Geary
  • Chief Medical & Chief Clinical Officer-Neurology: Lynn D. Kramer

Shareholders

  • Wellington Management Co. LLP (8.6%)
  • Nomura Asset Management Co., Ltd. (6.1%)
  • Government of Japan (5.0%)
  • Nippon Life Insurance Co. (3.8%)
  • Eisai Co., Ltd. (3.3%)
  • Asset Management One Co., Ltd. (3.0%)
  • Daiwa Asset Management Co. Ltd. (2.8%)
  • Nikko Asset Management Co., Ltd. (2.8%)
  • The Vanguard Group, Inc. (2.1%)
  • Resona Holdings, Inc. (2.1%)

Contact Details

  • Website:http://www.eisai.co.jp
  • Address: 4-6-10 Koishikawa, Bunkyo-Ku, Tokyo, 112-8088, Japan
  • Phone: +81.3.3817.3700

Related Companies

  • Eisai Innovation, Inc.
  • Eisai Europe Ltd.
  • Eisai LLC
  • Eisai Machinery China Co. Ltd.
  • Eisai Laboratorios S de RL de CV
  • Eisai GesmbH
  • Eisai Farmaceutica, Unipessoal Lda.
  • Eisai Clinical Research Singapore Pte Ltd.
  • Eisai Ltd. (Canada)
  • Eisai SA/NV
  • Eisai (Malaysia) Sdn. Bhd.
  • Eisai (Thailand) Marketing Co., Ltd.
  • Eisai AB
  • Eisai Pharma AG
  • Eisai (Singapore) Pte Ltd.
  • Eisai Co. Ltd. /Misato Factory/
  • Eisai Board Incentive Plan
  • Eisai Corporate Pension Fund
  • Eisai Pension Fund
  • Eisai China, Inc.
  • H3 Biomedicine, Inc.
  • Eisai R&D Management Co., Ltd.
  • Herusu Co., Ltd.
  • Gakuen Shoji Co., Ltd.
  • PT Eisai Indonesia
  • Eisai Taiwan, Inc.
  • Eisai (Hong Kong) Co., Ltd.
  • Eisai Australia Pty Ltd.
  • Eisai Pharmaceuticals India Pvt Ltd.
  • Eisai GmbH

Competitors

  • JW Holdings Corporation
  • Ipsen SA
  • Denali Therapeutics Inc.
  • Codiak BioSciences, Inc.
  • Mirati Therapeutics Inc.
  • Exelixis, Inc.
  • Seagen, Inc.
  • Blueprint Medicines Corp.
  • Arcutis Biotherapeutics Inc
  • Aprea Therapeutics, Inc.
  • Deciphera Pharmaceuticals, Inc.
  • Genkyotex SA
  • Aeolus Pharmaceuticals, Inc.
  • Infinity Pharmaceuticals, Inc.
  • Olema Pharmaceuticals, Inc.
  • AC Immune SA
  • Cortexyme, Inc.
  • Vivoryon Therapeutics N.V.
  • Calithera Biosciences, Inc.
  • Epizyme, Inc.
  • Xenon Pharmaceuticals Inc.
  • Aptinyx Inc
  • TCR2 Therapeutics, Inc.
  • Oncternal Therapeutics, Inc.
  • Hanall Biopharma Co., Ltd.
  • AVEO Pharmaceuticals, Inc.
  • Rain Therapeutics Inc
  • Relay Therapeutics, Inc.
  • Cassava Sciences, Inc.
  • Marinus Pharmaceuticals Inc
Last Updated on 15 Oct, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more